On august 29, 2019 Nordic Nanovector ASA (OSE: NANO) reported that it will host a R&D Day in Oslo on Tuesday, 17 September 2019 from 9:30am to 12:30pm CEST (Press release, Nordic Nanovector, AUG 29, 2019, View Source [SID1234553446]). The programme will include presentations from three external experts and by Nordic Nanovector’s senior management team. An update on the median Duration of Response (mDoR) of Betalutin treatment in the LYMRIT 37-01 trial will also be given during the day.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: Auditorium
To register to attend, please e-mail [email protected] by 13 September 2019.
The R&D Day will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media.
The presentations will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/2019.
The preliminary programme is as follows;
09.30-09.50 Nordic Nanovector’s pipeline – Strategic insights Eduardo Bravo, CEO
09.50-10.10 Radioimmunotherapy – Preclinical results with Betalutin and comparison of alpha and beta emitters Dr Jean-Pierre Pouget*
10.10-10.40 Future vision for R&D at Nordic Nanovector Dr Jostein Dahle, CSO
10:40-10:50 Introduction to clinical sessions Dr Lisa Rojkjaer, CMO
10.50-11.20 Unmet medical needs and therapeutic landscape for recurrent follicular and marginal zone lymphoma Prof. Pier Luigi Zinzani*
11:20-11:30 Coffee Break
11.30-12:00 Novel biologic combinations with Betalutin Dr Arne Kolstad*
12.00-12.20 BLA readiness: CMC commercial plans Dr Marco Renoldi, COO
12.20-12.30 Q&A
*The external experts’ speakers are:
Dr J.P. Pouget, PhD, Radiobiology and targeted radiotherapy group Montpellier Cancer Research Institute (IRCM), French National Institute of Health and Medical Research (INSERM).
Prof. P. L. Zinzani, Professor of Hematology, Institute of Hematology "L. e A. Seràgnoli", University of Bologna.
Dr A. Kolstad MD, PhD, senior consultant in Medical Oncology and Radiation Therapy, Dept of Oncology Oslo University Hospital, The Norwegian Radium Hospital.